Pharmacologic Mydriasis Secondary to Topical Glycopyrronium Tosylate Cloths: Clinical Characterization From a Multicenter Analysis

Update Item Information
Title Pharmacologic Mydriasis Secondary to Topical Glycopyrronium Tosylate Cloths: Clinical Characterization From a Multicenter Analysis
Creator Aaron R. Kaufman; Shawn Gulati; John H. Pula; Timothy M. Janetos; Neena R. Cherayil; Eric Chiu; Emily Anne Shepherd; Karl C. Golnik; Enrique Garcia-Valenzuela; Peter W. MacIntosh; Brooke T. Johnson; Kimberlee M. Curnyn
Affiliation Department of Ophthalmology and Visual Sciences (ARK, SG, PWM, BTJ, KMC), Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois; NorthShore University Health System (JHP), Evanston, Illinois; Department of Ophthalmology (TMJ, NRC), Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Department of Neurology (NRC), Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Des Peres Eye Center (EC), Des Peres, Missouri; Department of Ophthalmology (EAS), Rush University Medical Center, Chicago, Illinois; Department of Ophthalmology (KCG), University of Cincinnati College of Medicine (KCG), Cincinnati, Ohio; Cincinnati Eye Institute (KCG), Cincinnati, Ohio; and Midwest Retina Consultants (EG-V), Arlington Heights, Illinois
Abstract Topical glycopyrronium tosylate (GT) is an anticholinergic medication for treatment of axillary hyperhidrosis. Pharmacologic mydriasis and anisocoria from topical GT has been reported and may be underrecognized. This study aims to clinically characterize patients presenting with pharmacologic mydriasis from exposure to this medication.
Subject Adolescent; Anisocoria; Cholinergic Antagonists; Mydriasis; Retrospective Studies
OCR Text Show
Date 2022-12
Date Digital 2022-12
References 1. Lamb YN. Topical glycopyrronium tosylate in primary axillary hyperhidrosis: a profile of its use. Clin Drug Investig. 2019;39(11):1141-1147. - PMC - PubMed. 2. Chabicovsky M, Winkler S, Soeberdt M, Kilic A, Masur C, Abels C. Pharmacology, toxicology and clinical safety of glycopyrrolate. Toxicol Appl Pharmacol. 2019;370:154-169. - PubMed. 3. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743-749. - PMC - PubMed. 4. Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, Quiring J, Drew J, Pariser DM. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593-604. - PMC - PubMed. 5. Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, Drew J, Quiring J, Pariser DM. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128-138.e2. - PubMed.
Language eng
Format application/pdf
Type Text
Publication Type Journal Article
Source Journal of Neuro-Ophthalmology, December 2022, Volume 42, Issue 4
Collection Neuro-Ophthalmology Virtual Education Library: Journal of Neuro-Ophthalmology Archives: https://novel.utah.edu/jno/
Publisher Lippincott, Williams & Wilkins
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management © North American Neuro-Ophthalmology Society
ARK ark:/87278/s6dy471m
Setname ehsl_novel_jno
ID 2392987
Reference URL https://collections.lib.utah.edu/ark:/87278/s6dy471m
Back to Search Results